Jie Gao

Dr. Jie Gao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KLKun Liang
Kun Liang
SGSiyu Gui
Siyu Gui
XWXinchen Wang
Xinchen Wang
QWQianqian Wang
Qianqian Wang
JQJianchao Qiao
Jianchao Qiao
JGJie Gao
Jie Gao
To evaluate the effect of diabetic retinopathy (DR) status or severity on all-cause and cause-specific mortality among diabetic older adults in the United States using the most recent National Health and Nutrition Examination Survey (NHANES) follow-up mortality data. The severity of DR was graded according to the Early Treatment Diabetic Retinopathy Study (ETDRS) grading scale. Multiple covariate-adjusted Cox proportional hazards regression models, Fine and Gray competing risk regression models, and propensity score matching (PSM) methods were used to assess the risk of all-cause and cause-specific mortality in individuals with diabetes. All analyses adopted the weighted data and complex stratified design approach proposed by the NHANES guidelines. Time to death was calculated based on the time between baseline and date of death or December 31, 2019, whichever came first. Ultimately 1077 participants, representing 3,025,316 US non-hospitalized individuals with diabetes, were included in the final analysis. After a median follow-up of 12.24 years (IQR, 11.16–13.49), 379 participants were considered deceased from all-causes, with 43.90% suffering from DR, including mild DR (41.50%), moderate to severe DR (46.77%), and proliferative DR (PDR) (67.21%). DR was associated with increased all-cause, cardiovascular disease (CVD) and diabetes mellitus (DM)-specific mortality, which remained consistent after propensity score matching (PSM). Results of DR grading assessment suggested that the presence of mild, moderate to severe NPDR was significantly associated with increased risk of all-cause and CVD-specific mortality, while the presence and severity of any DR was associated with increased DM-specific mortality, with a positive trend. The presence of DR in elderly individuals with diabetes is significantly associated with the elevated all-cause and CVD mortality. The grading or severity of DR may reflect the severity of cardiovascular disease status and overall mortality risk in patients with diabetes.

8 December 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XWXinchen Wang
Xinchen Wang
SGSiyu Gui
Siyu Gui
XLXiaoyan Liu
Xiaoyan Liu
YTYumei Tao
Yumei Tao
JGJie Gao
Jie Gao
HLHeting Liu
Heting Liu
Dry age-related macular degeneration (AMD) is characterized by retinal pigment epithelium (RPE) barrier dysfunction, and currently lacks effective treatmen

23 October 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XWXinchen Wang
Xinchen Wang
SGSiyu Gui
Siyu Gui
XLXiaoyan Liu
Xiaoyan Liu
ZHZhihao Huang
Zhihao Huang
HLHeting Liu
Heting Liu
JGJie Gao
Jie Gao

24 March 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SGSiyu Gui
Siyu Gui
XWXinchen Wang
Xinchen Wang
QWQianqian Wang
Qianqian Wang
LZLan Zhong
Lan Zhong
JQJianchao Qiao
Jianchao Qiao
JGJie Gao
Jie Gao
To investigate and describe the impact of nonrefractive visual impairment (NVI) and its severity on all-cause and cause-specific mortality, along with the latest estimations. Cox proportional hazards regression models with multiple covariate adjustments and Fine-Gray competing risk regression models assessed the risk of all-cause and specific-cause mortality. Propensity score matching (PSM) was employed to achieve covariate balance. Among 7 961 participants (representing 171 383 125 non-institutionalized US individuals), baseline NVI was present in 350 participants (4.40%), with 313 (3.93%) having mild NVI and 37 (0.47%) having severe NVI. Both any NVI and Severe NVI were associated with increased all-cause and diabetes mellitus (DM)-related mortality. After PSM, the results remained consistent (for all-cause mortality: HR, 1.34; 95% CI, 1.05–1.70; for DM-related mortality: HR, 3.54; 95% CI, 1.15–10.97). Severity analysis demonstrated a significant trend between increasing NVI severity and elevated risks of all-cause and DM-specific mortality. Our findings confirm that NVI and its severity are independent risk factors for all-cause and DM-specific mortality among the US population. This highlights the importance of regular visual acuity examinations, particularly for NVI screening, especially in individuals with diabetes.

9 September 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YTYulin Tao
Yulin Tao
BZBingxu Zha
Bingxu Zha
FZFangpu Zhang
Fangpu Zhang
WDWenrui Du
Wenrui Du
SLSiyu Lin
Siyu Lin
ZJZhengxuan Jiang
Zhengxuan Jiang
Diabetic retinopathy (DR) is a leading global cause of vision loss, closely linked to hyperglycemia-induced oxidative stress, chronic inflammation, and pathological angiogenesis. Natural antioxidants exhibit great therapeutic potential against DR but are severely limited by poor solubility, low bioavailability, and insufficient ocular delivery. This review systematically summarizes the classification, pharmacological mechanisms, and therapeutic values of natural antioxidants in DR, and highlights advances in nanotechnology-based delivery systems to improve efficacy and clinical translation. We integrate preclinical and clinical studies focusing on key pathways including Nrf2/HO-1, NF-κB, NLRP3 inflammasome, and VEGF/HIF-1α. Flavonoids, polyphenols, carotenoids, and alkaloids exert multi-target effects by scavenging ROS, suppressing inflammation, and inhibiting pathological angiogenesis. Nanocarriers including lipid–polymer hybrid nanoparticles, self-nanoemulsifying drug delivery systems (SNEDDS), nanozymes, and lignin-based hydrogels significantly enhance solubility, corneal penetration, retinal targeting, and therapeutic efficacy. Representative nanoformulations effectively alleviate retinal oxidative damage, inflammation, and neovascularization. Natural antioxidants are promising DR candidates, and nanotechnology overcomes translational barriers. This review offers updated insights for developing natural product-based nanomedicines and proposes standardized formulations, biomarker-guided personalized therapy, and multi-target strategies to accelerate clinical translation.